|1.84||-0.0800||-4.17%||Vol 1.81M||1Y Perf -91.53%|
|Oct 3rd, 2023 16:00 DELAYED|
|- -||-0.04 -2.09%|
|Target Price||54.44||Analyst Rating||Moderate Buy 2.48|
|Potential %||2.86K||Finscreener Ranking||★★★★+ 56.32|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 53.53|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 66.69|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||-0.23||Earnings Rating||Neutral|
|Market Cap||181.35M||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Nov 2023|
|Estimated EPS Next Report||-0.59|
|EPS Growth Next 5 Years %||22.20|
|Avg. Weekly Volume||1.43M|
|Avg. Monthly Volume||3.21M|
|Avg. Quarterly Volume||2.21M|
Fate Therapeutics Inc. (NASDAQ: FATE) stock closed at 1.92 per share at the end of the most recent trading day (a -9.43% change compared to the prior day closing price) with a volume of 1.52M shares and market capitalization of 181.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 279 people. Fate Therapeutics Inc. CEO is J. Scott Wolchko.
The one-year performance of Fate Therapeutics Inc. stock is -91.53%, while year-to-date (YTD) performance is -80.97%. FATE stock has a five-year performance of -88.05%. Its 52-week range is between 1.89 and 23.96, which gives FATE stock a 52-week price range ratio of -0.23%
Fate Therapeutics Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.80, a price-to-sale (PS) ratio of 9.86, a price to cashflow ratio of -, a PEG ratio of -0.06, a ROA of -37.13%, a ROC of -40.49% and a ROE of -51.73%. The company’s profit margin is -%, its EBITDA margin is -430.90%, and its revenue ttm is $51.94 Million , which makes it $0.53 revenue per share.
Of the last four earnings reports from Fate Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.59 for the next earnings report. Fate Therapeutics Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Fate Therapeutics Inc. is Moderate Buy (2.48), with a target price of $54.44, which is +2 858.70% compared to the current price. The earnings rating for Fate Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fate Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Fate Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.58, ATR14 : 0.19, CCI20 : -124.97, Chaikin Money Flow : -0.24, MACD : -0.25, Money Flow Index : 24.64, ROC : -18.64, RSI : 31.16, STOCH (14,3) : 4.05, STOCH RSI : 0.14, UO : 36.16, Williams %R : -95.95), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fate Therapeutics Inc. in the last 12-months were: Bahram Valamehr (Option Excercise at a value of $580), Bahram Valamehr (Sold 10 917 shares of value $57 205 ), Chu Yu-Waye (Sold 10 357 shares of value $57 651 ), Cindy R. Tahl (Sold 11 553 shares of value $60 538 ), Cindy Tahl (Sold 11 553 shares of value $60 538 ), Dulac Edward (Sold 7 331 shares of value $38 414 ), Dulac Edward J III (Sold 5 182 shares of value $25 029 ), Edward J. Dulac (Sold 7 331 shares of value $38 414 ), J. Scott Wolchko (Sold 45 907 shares of value $240 553 ), John D. Mendlein (Option Excercise at a value of $38 992), Mark Plavsic (Sold 3 418 shares of value $17 910 ), Plavsic Mark (Sold 3 418 shares of value $17 910 ), Powl Brian T. (Sold 3 854 shares of value $18 769 ), Valamehr Bahram (Option Excercise at a value of $580), Valamehr Bahram (Sold 10 917 shares of value $57 205 ), Wolchko J. (Sold 45 907 shares of value $240 553 ), Xu Yuan (Sold 4 092 shares of value $21 652 ), Yu-Waye Chu (Sold 10 357 shares of value $57 651 )
Thu, 10 Aug 2023 07:26 GMT Fate Therapeutics (FATE) Gets a Buy from Barclays- TipRanks. All rights reserved.
Wed, 09 Aug 2023 04:10 GMT Analysts Top Healthcare Picks: Fate Therapeutics (FATE), Royalty Pharma (RPRX)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.